Bragar Eagel & Squire, P.C. reminds Dr. Reddy’s Laboratories
Ltd. (NYSE:RDY) investors that it is investigating potential claims on
their behalf concerning whether the company’s officers and board of
directors violated the federal securities laws.
On November 6, 2015, Dr. Reddy’s disclosed that it received a warning
letter from the U.S. Food and Drug Administration over inadequate
quality control procedures at three manufacturing plants in India. Dr.
Reddy’s said the FDA warning meant it would not receive U.S. approvals
for drugs made at the plants until it fixed the problems. The
manufacturing plants account for more than 10% of Dr. Reddy’s sales.
Following this news, shares of Dr. Reddy’s fell $11.75 per share, or
over 18%, to close at $53.50 per share on November 6, 2015.
If you purchased Dr. Reddy’s securities, have information or would like
to learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters
please contact J. Brandon Walker, Esq. by email at investigations@bespc.com,
or telephone at (212) 355-4648, or by filling
out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating
in commercial and securities litigation. For additional information,
please go to www.bespc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202006471/en/
Copyright Business Wire 2015